Departed
David Beers
Chief Financial Officer
CELU ·
Celularity Inc
terminated the employment of David Beers, its Chief Financial Officer without cause
CELU
Celularity Inc
Saved in this browser
Ready 8-Ks
19
Latest filing
Apr 21, 2026 23:59 UTC
Top materiality
0.85
Event mix
other_material ×10 · leadership ×4 · debt ×3
Sentiment
3 pos · 4 neg · 12 neu
Executive change
recent →
Recent 8-K filings for CELU
Highest-materiality recent filing
Celularity retires all $41.6M senior secured debt via IP sale and license-back deal
- Retired all $32M principal plus $9.6M accrued interest on senior secured loans for total $41.6M.
- Sold IP assets to Celeniv for $33,812,230; licensed back exclusively with five-year repurchase option.
-
Celularity closes $13.3M NexGel asset sale; Helena default notice on $1.97M note
Closed asset sale to NexGel for $13.3M ($8.3M cash + $5M note), retired ~$13M debt.
-
Celularity licenses biomaterials portfolio for up to $35M; retains manufacturing, cuts costs
Up to $35M cash: $15M upfront plus $20M milestone payments based on net sales targets.
-
Celularity CFO Joseph DosSantos departs; John Sprague named acting CFO
Joseph DosSantos left as SVP Finance and Acting CFO on Feb 27, 2026 for personal reasons.
-
Celularity amends SVP Haines' agreement; severance doubled, COBRA extended, equity accelerated
Comp Committee approved amendment to John Haines' employment agreement on Jan 16, 2026.
-
Celularity closes $10M financing with Philip A. Barach; issues senior secured and convertible notes
Gross proceeds at closing: $10.0M; potential additional $2.0M subject to conditions.
-
Celularity annual meeting: directors elected despite majority withheld; equity plan increase fails
Class I directors Peter Diamandis, Diane Parks, Geoffrey Ling elected; each received >4.5M votes for but >9.5M withheld.
-
Celularity receives FDA warning letter over Interfyl marketing claims
FDA warning letter received Dec 1, 2025, regarding marketing material for Interfyl (human connective tissue matrix).
-
Celularity raises $2M initial tranche in $6.67M private placement of Series A Preferred and warrants
Series A Preferred shares sold at 90% of stated value; $2M initial tranche closed Oct 24, 2025.
-
Nasdaq confirms Celularity compliant with listing rule after late 10-Qs; deficiency closed
Nasdaq notified Celularity on Sept 2, 2025 that it has regained compliance with Listing Rule 5250(c)(1).
-
Celularity retires all $41.6M senior secured debt via IP sale and license-back deal
Retired all $32M principal plus $9.6M accrued interest on senior secured loans for total $41.6M.
-
Celularity invests $2.9M in Defeye preferred stock; gets Nasdaq extension to Aug 31 for late filings
Acquired 7,198.6 shares of Defeye Series Seed-2 Preferred Stock for $2.89M in product purchase credits.
-
Celularity issues $6.81M promissory note and warrant to investor Lim Kok Thay
Issued $6,812,230 promissory note to Lim Kok Thay, 2% interest, matures March 21, 2026, secured by all company assets.
-
Celularity raises $2M via private placement of 1.23M shares and warrants
Issued 1,230,769 shares of common stock and warrants to purchase 1,230,769 shares at $1.625 per unit.
-
Celularity reprices warrants for Starr and RWI, issues new warrants under forbearance amendments
Repriced Starr warrants to $1.692/share; issued new warrant for 100,000 shares.
-
Celularity raises $1.035M in private placement of 739,286 shares at $1.40/share
Issue and sale of 739,286 shares of Class A common stock at $1.40 per share for gross proceeds of $1,035,000.
-
Celularity terminates CFO Beers without cause; names DosSantos interim CFO
CFO David Beers terminated without cause effective June 10, 2025; severance subject to release.
-
Celularity appoints Vincent LeVien as Class II director, effective June 5, 2025
Vincent LeVien appointed to Board as Class II director, serving until 2026 Annual Meeting.
-
Celularity extends convertible note maturity to Aug 15, 2025; issues 100K shares
Maturity of Convertible Promissory Note (dated March 13, 2024) extended from May 12, 2025 to August 15, 2025.
-
Director Dean Kehler resigns from Celularity board effective May 14, 2025
Dean Kehler resigned as a director of Celularity Inc. on May 14, 2025.
Executive changes
Appointed
(interim)
Joseph DosSantos
interim CFO
CELU ·
Celularity Inc
appointed Joseph DosSantos, its current Senior Vice President Finance, as the Company's interim CFO while the Company conducts a search for a new CFO.
Appointed
Vincent LeVien
Class II director
CELU ·
Celularity Inc
On June 5, 2025, the Board of Directors of Celularity Inc. (the “Company”) appointed Vincent LeVien as a Class II director of the Company to serve until the Annual Meeting of Stockholders to be held in 2026.
Departed
Dean Kehler
director
CELU ·
Celularity Inc
On May 14, 2025, Dean Kehler, a director of Celularity Inc. (the “Company”), resigned as a member of the Board of Directors of the Company.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material